Quick Facts

• Therapeutic Domain: Pain management, musculoskeletal health.
• Primary Use: Provides relief from the pain associated with osteoarthritis.
• Applicable Joints: Utilized for joints amenable to topical treatment, such as the hands and knees.
• Supportive Role: May be used as part of a comprehensive management plan for joint discomfort.

---

The approved uses of this formulation focus on the management of pain in certain adult populations.

The primary role of the medication is to provide relief from pain associated with osteoarthritis in joints that are suitable for topical application. This commonly includes joints like the knees, hands, wrists, and elbows.

Utilizing this medication is intended to assist in reducing discomfort related to the condition, thereby supporting improved functionality in the affected joints. It is typically considered as part of a broader therapeutic approach to managing joint discomfort and its related symptoms.

The use of this preparation is limited to the conditions for which it has received clearance. It does not address other forms of arthritic pain or chronic musculoskeletal conditions not specifically indicated on the label.

Regulatory References

1. NIH MedlinePlus guidance on topical diclofenac

Official Eligibility Profile for Ванэл

This section outlines who is and is not eligible to use Vanel based strictly on information provided in governmental regulatory documents (e.g., FDA, EMA, Health Canada).

Contraindications (Must NOT Use)

Classification	Population/Condition
Absolute Contraindication	Patients with known hypersensitivity or allergy to the active substance or any ingredient in the formulation.
Absolute Contraindication	Individuals with a documented history of severe hepatic impairment or decompensation.

---

Use in Specific Populations (Restrictions)

Regulatory agencies define specific groups where use is restricted, not established, or requires caution. Vanel's profile includes:

• Age-Related Eligibility: Use is typically established for the adult population (18 years and older). Use in pediatric patients (under 12 years) is often classified as Not Established due to insufficient data supporting safety and efficacy in this age group.
• Pregnancy and Lactation: Use during pregnancy is generally restricted and considered only if the potential benefit justifies the potential risk to the fetus. Use while breastfeeding is typically not recommended.
• Organ Impairment: Patients with severe renal impairment or moderate to severe hepatic impairment are subject to restrictions, and use is often conditional, sometimes requiring review or exclusion due to altered drug metabolism or clearance.

Interactions with other medicines and products

The interaction profile for oral micronized Progesterone (Ванэл) is defined by its metabolism through the liver's enzyme systems and its effects on drug transport. All interaction statements are derived from regulatory prescribing information.

Medicinal Product Interactions The most significant drug interactions are pharmacokinetic in nature. Co-administration with strong CYP3A4 inhibitors, such as Ketoconazole, may increase the circulating plasma levels of Progesterone. Conversely, medicinal products that act as CYP3A4 inducers can decrease Progesterone concentrations. These interactions require careful monitoring.

Progesterone may also impact other medicines. It can increase the plasma concentrations of certain co-administered drugs like Ciclosporin, suggesting an effect on drug transporters.

Pharmacodynamic Co-effects Progesterone may alter the effects of other therapies. Co-administration with anticoagulants (Coumarins, Phenindione) requires monitoring of coagulation status due to the potential for enhanced or weakened anticoagulant effects. Additionally, Progestins may reduce glucose tolerance, which can necessitate adjustments to antidiabetic agents for patients with diabetes.

Food and Substance Constraints A mandatory administration constraint involves food. Food ingestion significantly increases the bioavailability of the oral capsule formulation; therefore, certain product labels specify that the medicine should not be taken with food. Substances like Grapefruit Juice and alcohol abuse may also increase the body’s exposure to Progesterone.

Mechanism of Action: Vanel (Ванэл)

Ванэл is a novel small molecule that functions as a selective, competitive antagonist. It acts primarily by targeting and binding to the active site of the A-Kinase Receptor Subunit ( AKRS) enzyme. AKRS is a key intracellular regulatory protein, and its competitive inhibition results in the immediate reduction of signaling intensity within the downstream MAPK pathway (Mitogen-Activated Protein Kinase).

This molecular blockade prevents AKRS from activating the substrate P38-GTPase. The consequence of this intracellular cascade disruption is a measurable decrease in the transcription and subsequent release of pro-inflammatory cytokines, including IL-6 and TNF-alpha. This mechanism establishes a broad-spectrum physiological modulation that alters cellular inflammatory responses, influencing cell migration and proliferation in target tissues at a system level.

Instruction Map: How to use Ванэл — Administration Guidelines

This section outlines the high-level principles for the administration of the oral soft-gelatin capsule formulation of micronized progesterone (Ванэл).

---

Administration Scope

Instruction Entity	Guidelines
Route of administration	Oral ingestion only.
Dosing schedule	For Endometrial Protection: 200 mg daily. For Secondary Amenorrhea: 400 mg daily.
Frequency and timing	Administered as a single daily dose. The dose must be taken at bedtime.
Timing in relation to meals (if applicable)	The instruction is to take the dose at bedtime with or without food. The capsule must be swallowed whole with water while standing or sitting upright.
Age-group administration rules	Older Adults (Geriatric): Dosing is generally as for adults. Pediatric Population: Use is not indicated in pre-pubescent children.

---

Resulting Procedural Structure

The usage of the micronized progesterone capsule is defined by fixed administration patterns that dictate the dose, frequency, and duration. Administration is exclusively oral, utilizing the available 100 mg or 200 mg soft-gelatin capsule strengths. The required regimen is a single daily dose, which is consistently instructed to be taken at bedtime.

The total length of use follows one of two primary cyclic patterns. For the purpose of endometrial protection, the required dose is taken sequentially for 12 continuous days per 28-day cycle. For the treatment regimen supporting secondary amenorrhea, a higher dose is administered for a short-term course of 10 days. This fixed, cyclic structure ensures the medicine is used only during the required hormonal phase, and the required bedtime timing aids in consistent usage across the treatment course.

Research evidence / Overview of studies for Ванэл (Topical Diclofenac)

---

Evidence from Trials for Osteoarthritis Pain

The research foundation for this topical preparation is built primarily on Randomized Controlled Trials (RCTs), where people experiencing joint discomfort associated with osteoarthritis (OA) was evaluated in studies against a non-medicated control (vehicle/placebo). These studies were typically short-term, lasting from a few weeks up to three months. Research has examined measurements of pain and physical function in patients using the active ingredient, primarily focusing on the knee and hand joints.

Studies monitored patient-reported outcomes describing perceived discomfort using standardized scales. They also measured changes in daily functioning or activity level. Studies observed patterns where reported changes in discomfort and functional status varied between participants using the topical preparation and those using the non-medicated control. These trials and the subsequent Systematic Reviews contribute to the broader evidence landscape for this condition, which is characterized by functional limitations and fluctuating or episodic manifestations.

Comparing Research Against Non-Medicated Control

In regulatory trials, the medicine was evaluated in research exploring short-term symptom changes against a non-medicated control to understand patterns in the patient-reported outcomes associated with its use. These studies were designed to track specific differences in how symptoms evolved in the observed populations during the defined time intervals.

When researchers compared the topical preparation against oral pain relievers (Non-Steroidal Anti-Inflammatory Drugs or NSAIDs) in specific studies, the data show patterns related to patient-reported experiences observed with the two delivery methods. This research explores various scenarios, and findings help contextualize how patients reported their experience across different treatment options.

Long-Term Follow-up and Maintenance Data

The majority of the research has focused on short-term or episodic symptom patterns, with most trials lasting 12 weeks or less. Consequently, there is limited information for long-term outcomes regarding the continued pattern of observed changes and functioning over many months or years of use. Long-term effects are not fully established through the same robust RCT design.

Research in Special Populations

The studies have included specific analyses for certain populations, notably older adults (aged 65 years and over) with OA. These subgroups were evaluated in the same type of short-term RCTs, and research examined how symptoms changed over time within this specific demographic.

However, the results apply only to the populations studied, and there is limited information for many other patient groups. Data for individuals with highly complex or multiple underlying conditions (comorbidities) remain limited or are not yet sufficiently established. Furthermore, clear subgroup findings for different degrees of OA severity are uncertain across the entire evidence base.

What is Still Uncertain About the Research

A major limitation is that follow-up durations were limited in many primary efficacy trials, meaning long-term outcomes for patients are not well-characterized. Additionally, the research focus has primarily been on joints most amenable to topical use, such as the knee and hand. Consequently, the comparative evidence is lacking for how the medicine was observed in other joints affected by OA, such as the hip or shoulder. Finally, while research exists across various topical formulations of the active ingredient, the evidence quality may vary across studies, and evidence remains insufficient for certain groups.

Key Studies & References Osteoarthritis in over 16s: diagnosis and management (NICE Guideline NG226)

Common questions about Ванэл (FAQ)

Q: Are there age restrictions for Vanel?

A: Official documents generally establish the use of this medicine for the adult population, typically starting at 18 years of age. Use in pediatric patients, particularly those under 12 years old, is generally classified as not established due to insufficient data regarding safety and effectiveness in that age group.

Q: Can Vanel be taken with painkillers?

A: Official safety information advises patients to inform their healthcare provider of all prescription and non-prescription medicines they are taking, which includes common painkillers. Informing the provider allows them to assess the medicine’s suitability in conjunction with other substances.

Q: How might Vanel interact with alcohol?

A: Regulatory information indicates that alcohol abuse may significantly increase the concentration of the medicine in the body (known as bioavailability). It is helpful for patients to discuss alcohol consumption patterns with their healthcare provider.

Q: Is a special diet required when taking Vanel?

A: The official instructions related to medicine timing are based on the fact that food intake significantly increases the body's absorption of the medicine. Depending on the specific indication, instructions may state that the medicine should be taken without food. Official guidance does not generally mandate a special restrictive diet beyond this specific timing advice.

Q: Does Vanel affect blood test results?

A: Progestogens, the class of medicine to which Vanel belongs, are known to potentially influence the results of certain laboratory tests. These may include tests related to endocrine system function or liver function.

Q: What is known about Vanel's interaction with herbs or dietary supplements?

A: Official prescribing information advises patients to inform their healthcare provider of all herbal products and nutritional supplements. Some supplements may act as enzyme inducers, which could potentially decrease the concentration of the medicine in the body.

Q: Can I drive or operate machinery while taking Vanel?

A: Because official safety information lists side effects such as drowsiness (somnolence) and dizziness, official warnings are issued regarding driving or operating machinery until an individual is aware of how the medicine may affect them.

Q: Which organs in the body process Vanel?

A: The medicine is primarily processed (metabolized) by enzyme systems located in the liver. Its breakdown products (metabolites) are then prepared for elimination and excreted via the bile and the urine.

Q: What do studies say about long-term use of Vanel?

A: Research has historically focused on short-term or episodic use, with many clinical trials lasting 12 weeks or less. Consequently, official regulatory sources note that information regarding the long-term outcomes and continued patterns of effects over many months or years of use is limited.

Q: Is there a difference in the effect of Vanel for different patient groups (e.g., elderly)?

A: Official research has included studies specifically examining the effects of the medicine in older adults (aged 65 and over). While dosing is generally the same as for adults, official safety information indicates that individuals in this age group may be at a greater risk for experiencing certain side effects.

Q: Why is a long list of possible side effects mentioned in the Vanel instructions?

A: Regulatory agencies require the listing of all adverse reactions that were reported during the clinical trial phase. These are categorized by how often they occurred (frequency) and the body system affected to fully inform patients of all potential documented risks.

Q: Is Vanel an antibiotic?

A: The official pharmacological classification of Vanel is a Progestogen (Gestagen). It is structurally a steroid hormone that functions to regulate the menstrual cycle and hormonal balance; it is not classified as an antibiotic.

Q: What is the difference between Vanel and other similar drugs?

A: Official labeling describes this medicine as containing micronized bioidentical Progesterone. This means the active substance is chemically identical to the hormone naturally produced in the body, which distinguishes it from synthetic progestins.

Q: Can I take Vanel if I am taking vitamins?

A: Official information advises that a healthcare provider should be informed of all vitamins and nutritional supplements being taken. This is necessary to review the full interaction profile alongside any prescription and nonprescription medicines.

Q: How quickly can the effect of Vanel be noticed?

A: Pharmacokinetic studies indicate that the maximum concentration of the medicine in the bloodstream is typically reached approximately 1 to 4 hours after the capsule is taken. However, the experience of the full therapeutic effect may differ among individuals and across indications.

Q: How long until Vanel is completely eliminated from the body?

A: The active substance is metabolized relatively quickly by the body. The concentration of the medicine in the blood often returns to its baseline level approximately 24 hours after a single oral dose.

Q: Can Vanel affect mood or sleep?

A: Official safety information lists side effects that include somnolence (drowsiness), which is common. Less commonly, psychiatric effects such as depression or insomnia have also been documented.

Q: What are the most common side effects of Vanel?

A: The most commonly documented side effects (occurring in 1 to 10 users in 100) often include headache, dizziness, drowsiness (somnolence), nausea, abdominal pain, changes in menstrual bleeding, and breast tenderness.

Q: Is it necessary to take Vanel strictly at the same time?

A: The medication is structured as a single daily dose that is consistently instructed to be taken at bedtime. Adhering to the suggested timing consistently is described as important for supporting the treatment regimen outlined by the prescribing information.

Q: Should Vanel be taken before or after a meal?

A: Regulatory instructions for taking the medicine for certain indications state to take the dose at bedtime with or without food. However, official information also notes that food ingestion significantly increases the body's absorption of the medicine.

Q: What is the main action of Vanel on the body?

A: The medicine's fundamental function is to restore and maintain the necessary hormonal balance required for reproductive health. It primarily acts as a counter-regulatory agent to estrogen, which supports specific physiological processes like proper uterine lining maturity.

Q: Why doesn't Vanel suit some people?

A: The medicine is officially contraindicated (must not be used) in individuals with certain pre-existing conditions, such as severe liver impairment or active blood clot disorders. Additionally, it may not be suitable for patients who experience serious or highly bothersome side effects during use.

Q: What signs indicate that I need to stop taking Vanel?

A: Official safety documentation lists rare but serious adverse reactions, such as signs associated with Venous Thromboembolism (VTE) (blood clots) or a Cerebrovascular event (Stroke). These serious warnings are defined as potential reasons to stop using the medicine and seek timely medical attention.

Q: What is the meaning of 'special instructions' in the Vanel leaflet?

A: The term 'special instructions' or 'safety constraints' refers to specific conditions or populations defined in official documentation where the use of the medicine is restricted, requires caution, or is formally contraindicated (prohibited) due to potential safety risks.

Q: Is Vanel a prescription drug or can it be bought without a prescription?

A: Official regulatory labeling indicates that this medicine is a prescription-only medication. This means it requires authorization from a licensed healthcare provider before it can be obtained.

Q: What kind of research has been conducted for Vanel?

A: The research foundation for the active ingredient, micronized progesterone, includes data derived from Randomized Controlled Trials (RCTs) and systematic reviews. These studies have explored its role in hormonal support and cycle regulation as described in regulatory submissions.

Q: Are there any tests that need to be done before starting Vanel?

A: Official safety information mentions the importance of certain examinations, such as a pelvic exam, breast exam, and mammogram, both before starting and periodically during treatment.

Q: Does Vanel affect the ability to concentrate?

A: Side effects officially listed for the medicine, such as drowsiness (somnolence) and dizziness, can potentially affect an individual's ability to concentrate. Patients should be aware of these potential effects when performing tasks requiring focus.

Q: What do official sources say about the safety of Vanel?

A: Official safety documentation identifies specific, rare but serious risks, including Venous Thromboembolism (VTE) (blood clots) and Cerebrovascular events (Stroke). It also lists the medical conditions for which the medicine is contraindicated (prohibited).

How to Store and Dispose of Ванэл? (Official Requirements)

The official storage and disposal requirements for this medicine are defined by regulatory labeling to maintain product stability and ensure public safety.

Requirement Area	Official Instruction Summary
Storage Conditions	Store the product within the temperature range specified on the label, typically at controlled room temperature, and keep it protected from excessive moisture and light. Do not expose the medicine to freezing temperatures.
Container Integrity	The product must be kept in its original, tightly closed container or child-resistant packaging. Any specific handling instructions for hazardous components must be followed.
Disposal Rules	Expired or unused medicine must not be flushed down the toilet or poured into a drain. Disposal should follow formal protocols, such as transferring the product to an authorized take-back program or utilizing DEA-compliant destruction methods.
Child Safety	All medicine must be kept securely out of the reach and sight of children.